EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: SARTORIUS AG
/ Key word(s): Alliance
Göttingen, Germany, May 16, 2024
Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
The life science group Sartorius is expanding its multidisciplinary collaboration with NVIDIA to help enable the development of new and better therapies, combining Sartorius’ in-depth knowledge of life sciences and bioprocessing with NVIDIA’s AI-powered computing platforms and software. "Biological interactions are exceptionally complex. Making better use of data by integrating life science expertise with AI solutions is a promising approach to simplify and accelerate biopharma drug discovery and manufacturing progress. This expanded collaboration with NVIDIA will help result in relevant technological innovations for our customers and ultimately for patients," said Prof. Dr. Oscar-Werner Reif, Chief Technology Officer of Sartorius. Sartorius has been working with NVIDIA since 2020. The life science group has integrated NVIDIA's technology into its instruments, enabling edge computing applications of its live-cell imaging platform for commercialized AI assays in the lab. The focus of the collaboration has been on developing predictive AI models of stem cell-derived organoids to replace animal models in drug discovery and precision medicine. Sartorius is also using NVIDIA solutions for predictive bioprocess design and simulation tools for manufacturing innovative therapies. The expanded collaboration includes increasing adoption of the NVIDIA Clara suite of AI-powered computing platforms, software, and services in the Sartorius ecosystem. Plans involve creating and commercializing powerful foundational models based on Sartorius’ extensive and unique data sets. New predictive AI models, tools, and simulations for numerous application areas will also be available to Sartorius customers through the NVIDIA Clara suite and the NVIDIA DGX platform. In a forward-looking approach to innovation and technology integration in the biopharmaceutical sector, the collaboration will explore numerous advanced technologies, including the computer-based design and simulation of complex 3D-bioprinted spheroids and organoids or synthetic biological pathways and organisms designed based on Sartorius cell lines, to produce novel therapeutic agents and therapies. A profile of Sartorius Sartorius (XETRA: SRT3 | SRT) is a leading international partner of life sciences research and biopharmaceutical manufacturing. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2023, the company generated sales revenue of around 3.4 billion euros. Currently, around 14,600 employees are working for customers around the globe. Visit our Newsroom or follow us on LinkedIn. Contact Leona Malorny Head of External Communications +49 551 308 4067 leona.malorny@sartorius.com Additional features: File: 2024-05-16_Sartorius_Media Release_NVIDIA_Collaboration_en
16.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | SARTORIUS AG |
Otto-Brenner-Straße 20 | |
37079 Göttingen | |
Germany | |
Phone: | +49.(0)551-308.0 |
Fax: | +49.(0)551-308.3289 |
E-mail: | info@sartorius.com |
Internet: | www.sartorius.com |
ISIN: | DE0007165607, DE0007165631 |
WKN: | 716560 , 716563 |
Indices: | DAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1904837 |
End of News | EQS News Service |
|
1904837 16.05.2024 CET/CEST
Zur besseren Einschätzung der fundamentalen Entwicklung der jeweiligen Unternehmen bietet boersengefluester.de (BGFL) eine Übersicht mit den wesentlichen Kennzahlen zu Umsatz, Ergebnis, Cashflow und Dividende. Sämtliche Angaben werden manuell in unserer Datenbank erfasst – Quelle sind die jeweiligen Geschäftsberichte. Sofern es sich um Schätzungen für künftige Zahlen handelt, stammen sie durchweg von BGFL.
Die wichtigsten Finanzdaten auf einen Blick | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Umsatzerlöse1 | 1.566,03 | 1.826,97 | 2.335,66 | 3.449,22 | 4.174,70 | 3.395,70 | 3.400,00 | |
EBITDA1,2 | 405,00 | 495,80 | 636,70 | 1.134,26 | 1.410,40 | 962,70 | 955,00 | |
EBITDA-Marge3 | 25,86 | 27,14 | 27,26 | 32,89 | 33,78 | 28,35 | 28,09 | |
EBIT1,4 | 298,61 | 335,66 | 456,11 | 903,16 | 1.070,00 | 503,90 | 530,00 | |
EBIT-Marge5 | 19,07 | 18,37 | 19,53 | 26,18 | 25,63 | 14,84 | 15,59 | |
Jahresüberschuss1 | 197,48 | 218,74 | 299,56 | 426,98 | 655,40 | 290,00 | 205,00 | |
Netto-Marge6 | 12,61 | 11,97 | 12,83 | 12,38 | 15,70 | 8,54 | 6,03 | |
Cashflow1,7 | 244,52 | 377,19 | 511,53 | 865,81 | 734,20 | 853,60 | 880,00 | |
Ergebnis je Aktie8 | 2,56 | 3,06 | 4,37 | 8,08 | 9,57 | 4,94 | 2,90 | |
Dividende8 | 0,61 | 0,35 | 0,70 | 1,25 | 1,43 | 0,73 | 0,73 |
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: -
Alle relevanten Bewertungskennzahlen, Termine und sonstige Investor-Informationen zu Ihrer Aktie kompakt zusammengefasst. Gut zu wissen: Sämtliche Daten stammen von boersengefluester.de werden täglich aktualisiert. Damit sind Sie immer auf dem neuen Stand. Kurze Erkärungen zu den Kennzahlen bekommen Sie, wenn Sie mit dem Cursor bzw. der Maus auf das jeweilige Feld gehen.
INVESTOR-INFORMATIONEN | ||||||
©boersengefluester.de | ||||||
Sartorius ST | ||||||
WKN | ISIN | Rechtsform | Börsenwert | IPO | Einschätzung | Plus Code |
716560 | DE0007165607 | AG | 14.676,48 Mio € | 10.07.1990 | Halten | 9F3FHV2Q+JW |
KGV 2025e | KGV 10Y-Ø | BGFL-Ratio | Shiller-KGV | KBV | KCV | KUV |
44,10 | 39,18 | 1,13 | 40,56 | 5,05 | 15,47 | 4,32 |
Dividende '2022 in € |
Dividende '2023 in € |
Dividende '2024e in € |
Div.-Rendite '2024e in % |
1,43 | 0,73 | 0,73 | 0,41% |
Hauptversammlung | Q1-Zahlen | Q2-Zahlen | Q3-Zahlen | Bilanz-PK |
27.03.2025 | 18.04.2024 | 19.07.2024 | 17.10.2024 | 16.02.2024 |
Abstand 60-Tage-Linie | Abstand 200-Tage-Linie | Performance YtD | Kursveränderung 52 Wochen | IPO |
-4,84% | -12,84% | -33,43% | -32,80% | +2.483,86% |
Auf dem 2013 von Gereon Kruse gegründeten Finanzportal boersengefluester.de dreht sich alles um deutsche Aktien – mit klarem Schwerpunkt auf Nebenwerte. Neben klassischen redaktionellen Beiträgen sticht die Seite insbesondere durch eine Vielzahl an selbst entwickelten Analysetools hervor. Basis sämtlicher Tools ist eine komplett selbst gepflegte Datenbank für mehr als 650 Aktien. Damit erstellt boersengefluester.de Deutschlands größte Gewinn- und Dividendenprognose.